Wall Street brokerages forecast that Kura Oncology, Inc. (NASDAQ:KURA) will report ($0.37) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Kura Oncology’s earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.49). Kura Oncology also posted earnings per share of ($0.37) in the same quarter last year. The firm is expected to issue its next earnings report on Monday, November 6th.
On average, analysts expect that Kura Oncology will report full-year earnings of ($1.54) per share for the current year, with EPS estimates ranging from ($1.82) to ($1.35). For the next financial year, analysts forecast that the firm will post earnings of ($1.91) per share, with EPS estimates ranging from ($2.70) to ($1.35). Zacks’ EPS calculations are a mean average based on a survey of research firms that that provide coverage for Kura Oncology.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Monday, August 7th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03.
A number of research analysts have issued reports on KURA shares. Zacks Investment Research downgraded Kura Oncology from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup Inc. set a $13.00 price target on Kura Oncology and gave the company a “buy” rating in a report on Tuesday, August 8th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Wednesday, June 28th. Cowen and Company began coverage on Kura Oncology in a report on Thursday, September 7th. They issued an “outperform” rating for the company. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Kura Oncology currently has an average rating of “Buy” and a consensus target price of $16.00.
Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Kura Oncology by 13.0% during the 2nd quarter. Vanguard Group Inc. now owns 433,868 shares of the company’s stock worth $4,035,000 after buying an additional 50,033 shares during the period. Morgan Stanley raised its stake in shares of Kura Oncology by 175.5% during the 1st quarter. Morgan Stanley now owns 430,428 shares of the company’s stock worth $3,788,000 after buying an additional 274,166 shares during the period. Alethea Capital Management LLC raised its stake in shares of Kura Oncology by 128.1% during the 2nd quarter. Alethea Capital Management LLC now owns 193,346 shares of the company’s stock worth $1,798,000 after buying an additional 108,577 shares during the period. State Street Corp acquired a new position in shares of Kura Oncology during the 2nd quarter worth approximately $1,394,000. Finally, Northern Trust Corp raised its stake in shares of Kura Oncology by 939.3% during the 2nd quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock worth $1,372,000 after buying an additional 133,293 shares during the period. 39.07% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Analysts Expect Kura Oncology, Inc. (KURA) Will Announce Earnings of -$0.37 Per Share” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/27/analysts-expect-kura-oncology-inc-kura-will-announce-earnings-of-0-37-per-share.html.
Kura Oncology (KURA) traded down 0.71% during midday trading on Friday, reaching $14.00. 1,018,501 shares of the company’s stock were exchanged. Kura Oncology has a 52 week low of $4.00 and a 52 week high of $15.30. The firm’s 50 day moving average is $11.80 and its 200 day moving average is $9.59. The firm’s market capitalization is $279.83 million.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Get a free copy of the Zacks research report on Kura Oncology (KURA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.